Enter your terms above and click the 'Search' button.

Showing articles 0 to 13 of 13 Filter Applied: immune checkpoint inhibitors (Click to remove) Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Ann Neurol 87:659-669, Dubey, D.,et al, 2020 Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies Neurol 92:663-674, Johansen, A.,et al, 2019 Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer Neurol 91:e985-e994, Touat, M.,et al, 2018 Progressive Hemiparesis and White Matter Abnormalities in an HIV-Negative Patient Neurol 100:1156-1163, Jabbari,E.,et al, 2023 In Patients with Melanoma Brain Metastases, is Combination Immune Checkpoint Inhibition a Safe and Effective First-Line Treatment? A Critically Appraised Topic Neurologist 27:290-297, Gritsch, D.,et al, 2022 Cranial Nerve Disorders Associated with Immune Checkpoint Inhibitors Neurol 96:e866-e875, Vogrig, A.,et al, 2021 Pembrolizumab-Induced Migrating Cortico-Subcortical Brain Lesions Ann Neurol 89:1255-1256, Lambert, N.,et al, 2021 Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum Ann Neurol 87:659-669, Dubey, D.,et al, 2020 Association of Innovations in Radiotherapy and Systemic Treatments with Clinical Outcomes in Patients with Melanoma Brain Metastasis From 2007 to 2016 JAMA doi:10.1001/JAMANETWORKOPEN.2020.8204, Brastianos, H.C.,et al, 2020 Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy NEJM 380:1597-1605, Cortese, I.,et al, 2019 Acute demyelinating polyneuropathy induced by nivolumab JNNP 89:435-437, Fukumoto, Y.,et al, 2018 Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain NEJM 379:722-730,789, Tawbi, H.A.,et al, 2018 Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016 Showing articles 0 to 13 of 13